MAL-5

MAL-5 is an experimental small molecule histone deacetylase (HDAC) inhibitor being investigated as a potential anti-metastatic therapy for breast cancer. Developed by researchers at the University of Sharjah and the University of Freiburg, MAL-5 has demonstrated preclinical efficacy in inhibiting the growth and invasion of breast cancer cell lines, including MCF-7 and MDA-MB-231. Mechanistically, treatment with MAL-5 significantly induces the expression of tissue inhibitor of metalloproteinases 2 (TIMP-2) at both the mRNA and protein levels, while simultaneously reducing the expression and enzymatic activity of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). This modulation of the TIMP/MMP signaling pathway effectively attenuates the invasive and metastatic capabilities of breast cancer cells.